Cytokines and Cancer

References

• Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Pallidino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor alpha effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943–945
   PubMed Web of Science ®Google Scholar
• Urabe A. Interferons for the treatment of hematological malignancies. Oncology 1994; 51: 137–141
   PubMedGoogle Scholar
• Topp M. S., Papadimitriou C. A., Eitelbach F., Oelman E., Koehler B., Oberberg D., VonMarschall Z., Reufi B., Stein H., Thiel E. Leuk. Lymph. 1995; 19: 319–328
   PubMed Web of Science ®Google Scholar
• Toi M., Bicknell R., Harris A. L. Inhibition of colon and breast carcinoma cell growth by interleukin 4. Cancer Res. 1992; 52: 275–279
   PubMed Web of Science ®Google Scholar
• Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-b2. Proc. Nat. Acad. Sci. 1988; 85: 8037–8041
   PubMed Web of Science ®Google Scholar
• Takizawa H., Ohtoshi T., Ohta K., Yamashita N., Hirohata S., Hirai K., Hiramatsu K., Ito K. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 1993; 53: 4175–4181
   PubMedGoogle Scholar
• Danforth D. N., Sgagias M. K. Interleukin 1 alpha and interleukin 6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993; 53: 1538–1545
   PubMedGoogle Scholar
• Raitano A. B., Korc M. Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gammainterferon receptors. Cancer Res. 1993; 53: 636–640
   PubMed Web of Science ®Google Scholar
• Totpal K., Aggarwal B. B. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res. 1991; 51: 4266–4270
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Taga T. Interleukin 6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593–597
   PubMed Web of Science ®Google Scholar
• Cimoli G., Russo P., Billi G., Mariani G. L., Rovini E. and Venturing M. Human granulocyte — macrophage colony — stimulating factor is a growth factor active on human ovarian cancer cells. J. Cancer Res. 1991; 82: 1196–1198
   Google Scholar
• Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. PNAS 1990; 87: 3092–3096
   PubMed Web of Science ®Google Scholar
• Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. IL6 functions as an autocrine growth factor in renal cell carcinoma. FEBS Lett. 1989; 250: 607–610
   PubMed Web of Science ®Google Scholar
• VanMeir E., Sawamura Y., Diserens A. C., Hamou M. F., de Tribolet N. Human glioblastoma cells release interleukin 6 in vivoin vitro. Cancer Res. 1990; 50: 6683–6688
   PubMedGoogle Scholar
• Erroi A., Sironi M., Chiaffarino F., Guo C. Z., Mengozzi M., Mantiovani A. IL1 and IL6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer 1989; 44: 795–801
   PubMedGoogle Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin 6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Wu S., Rodabaugh K., Martinez-Maza O., Watson J. M., Silverstein D. S., Boyer C. M., Peters W. P., Weinberg B., Berek J. S., Bast R. C., Jr. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin 1, interleukin 6 and tumor necrosis factor a. Am. J. Obst. Gynecol. 1992; 166: 997–1007
   PubMedGoogle Scholar
• De waal Malefyt R., Abrams J., Bennett B., Figdor C. G., De Vries J. E. Interleukin 10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL10 produced by monocytes. J. Exp. Med. 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., Zhang Q. J., Masucci M. G., Kiessling R. Interleukin 10 pretreatment protects target cells from tumor and allospecific cytotoxic T cells and down regulates HLA class I expression. J. Exp. Med. 1994; 180: 2371–2376
   PubMed Web of Science ®Google Scholar
• Hiscox S., Hallett M. B., Puntis M. C., Jiang W. G. Inhibition of cancer cell motility and invasion by interleukin 12. Clin. Exp. Metast. 1995; 5: 396–404
   Google Scholar
• Tamm I., Cardinale I., Krueger J., Murphy J. S., May L. T., Sehgal P. B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med. 1989; 170: 1649–1669
   PubMed Web of Science ®Google Scholar
• Welch D. R., Fabra A., Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Nat. Acad. Sci. 1990; 87: 7678–7682
   PubMed Web of Science ®Google Scholar
• Arrick B. A., Lopez A. R., Elfman F., Ebener R., Damsky C. H., Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell. Biol. 1992; 118: 715–726
   PubMedGoogle Scholar
• Krasagakis K., Garbe C., Zouboulis C. C., Orfanos C. E. Growth control of melanoma cells and melanocytes by cytokines. Recent Results. Cancer Res 1995; 139: 169–182
   Google Scholar
• Lu C., Vickers M. F., Kerbel R. S. Interleukin 6: a fibroblast derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Nat. Acad. Sci. 1992; 89: 9215–9219
   PubMedGoogle Scholar
• Woodworth C. D., McMullin E., Iglesias M., Plowman G. D. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Nat. Acad. Sci. 1995; 92: 2840–2844
   PubMed Web of Science ®Google Scholar
• Bast R. C., Boyer C. M., Jacobs I., Xu F. J., Wu S., Wiener J., Kohler M., Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer 1993; 71: 1597–1601
   PubMed Web of Science ®Google Scholar
• Yamamura M., Modlin R. L., Ohmen J. D., Moy R. L. Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest. 1993; 91: 1005–1010
   PubMedGoogle Scholar
• Nakagomi H., Pisa P., Pisa E. K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. Lack of interleukin 2 (IL2) expression and selective expression of IL10 mRNA in human renal cell carcinoma. Int. J. Cancer 1995; 63: 366–371
   PubMed Web of Science ®Google Scholar
• Lüscher U., Filgueira L., Juretic A., Zuber M., Lüscher N. J., Heberer M., Spagnoli G. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 1994; 57: 612
   PubMed Web of Science ®Google Scholar
• Tartour E., Gey A., Sastre-Garau X., Pannetier C., Mosseri V., Kourilsky P., Fridman W. H. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res. 1994; 54: 6243–6248
   PubMedGoogle Scholar
• Meyers F. J., Gumerlock P. H., Kawasaki E. S., Wang A. M., de Vere White R. W., Erlich H. A. Bladder cancer: human leukocyte antigen II, interleukin 6 and interleukin 6 receptor expression determined by the polymerase chain reaction. Cancer 1991; 67: 2087–2095
   PubMed Web of Science ®Google Scholar
• Vowels B. R., Lessin S. R., Cassin M., Jaworsky C., Benoit B., Wolfe J. T., Rook A. H. TH2 cytokine mRNA expression in skin in cutaneous T cell lymphoma. J. Invest Dermatol. 1994; 103: 669–673
   PubMed Web of Science ®Google Scholar
• Weng X., Mathiot C., Lando D., Fridman W. H. Inhibition of Lak cells by IL2-activated monocytes: role of TGF-β and PGE2. The Cancer Journal 1991; 4: 307–315
   Google Scholar
• Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., Zhang Q. J., Masucci M. G., Kiessling R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 1994; 180(6)2371–2376
   PubMed Web of Science ®Google Scholar
• Miescher S., Whiteside T. L., Carrel S., vonFliedner V. Functional properties of tumor infiltrating and blood lymphocytes in patients with soüd tumors: effect of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 1986; 136: 1899–1907
   PubMed Web of Science ®Google Scholar
• Tartour E., Latour S., Mathiot C., Thiounn N., Mosseri V., Joyeux Dubois I., d'Enghien C., Lee R., Debre B., Fridman W. H. Variable expression of CD3-Z chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int. J. Cancer 1995; 63: 205–212
   PubMed Web of Science ®Google Scholar
• Vitolo D., Zerbe T., Kanbour A., Dahl C., Herberman R. B., Whiteside T. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int. J. Cancer 1992; 51: 573–580
   PubMedGoogle Scholar
• Lüscher U., Filgueira L., Juretic A., Zuber M., Lüscher N. J., Heberer M., Spagnoli G. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 1994; 57: 612–619
   PubMed Web of Science ®Google Scholar
• Roszman T., Elliott L., Brooks W. Modulation of T-cell function by gliomas. Immunol. Today 1991; 12: 370–374
   PubMedGoogle Scholar
• Reinhold U., Abken H., Kukel S., Goeden B., Uerlich M., Neumann U., Kreysel H. W. Tumor-infiltrating lymphocytes isolated from a Ki-1-positive large cell lymphoma of the skin. Cancer 1991; 68: 2155–2160
   PubMedGoogle Scholar
• Erroi A., Sironi M., Chiaffarino F., Guo C. Z., Mengozzi M., Mantovani A. IL1 and IL6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer 1989; 44: 795–801
   PubMedGoogle Scholar
• Beissert S., Bergholz M., Waase I., Lepsien G., Schauer A., Pfizenmaier K., Kronke M. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc. Nat. Acad. Sci. 1989; 86: 5064–5068
   PubMedGoogle Scholar
• Tartour E., Pannetier C., Mathiot C., Teillaud J. L., Sautès C., Kourilsky P., Fridman W. H. Prognostic value of cytokine and soluble Fcγ receptor assays in oncology. Immunol. letter 1995; 44: 145–148
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Burdin N., Rousset F., Lenoir G., Biron P., Philip T., Banchereau J., Favrot M. Serum interleukin 10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169–2174
   PubMed Web of Science ®Google Scholar
• Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992; 70: 709–713
   PubMed Web of Science ®Google Scholar
• Gorsch S. M., Memoli V. A., Stukel T. A., Gold L. I., Arrick B. A. Immuno-histochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992; 52(24)6949–6952
   PubMedGoogle Scholar
• Okamoto T., Watanabe N., Yamauchi N., Tsuji Y., Tsuji N., Itoh Y., Neda H., Niitsu Y. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res. 1992; 52: 5278–5281
   PubMed Web of Science ®Google Scholar
• Spriggs D., Imamura K., Rodriguez C., Horiguchi J., Kufe D. W. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Nat. Acad. Sci. 1987; 84: 6563–6566
   PubMed Web of Science ®Google Scholar
• Lu C., Kerbel R. S. Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol. 1993; 120: 1281–1288
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Mezrrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F., Philip T., Favrot M. Serum levels of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317–3322
   PubMed Web of Science ®Google Scholar
• Tartour E., Dorval T., Mosseri V., Deneux L., Mathiot C., Brailly H., Montero F., Joyeux I., Pouillart P., Fridman W. H. Serum interleukin 6 and C reactive protein levels correlate with resistance to IL2 therapy and poor survival in melanoma patients. Br. J. Cancer 1994; 69: 911–913
   PubMedGoogle Scholar
• Herrmann F., Helfrich S. G., Lindemann A., Schleiermacher E., Huber C., Merstelmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J. Clin. Oncol. 1992; 10: 631–634
   PubMed Web of Science ®Google Scholar
• Mizutami Y., Bonavida B., Koishihara, et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 moniclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995; 55: 590–596
   PubMedGoogle Scholar
• Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-Dtamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995; 55: 4633–4639
   PubMed Web of Science ®Google Scholar
• Scambia G., Testa U., Panici P. B., Martcucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., Mancuso S. Interleukin 6 serum levels in patients with gynecological tumors. Int. J. Cancer 1994; 57: 318–323
   PubMed Web of Science ®Google Scholar
• Yoneda T., Nakai M., Moriyama K., Scott L., Ida N., Kunitomo T., Mundy G. R. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 1993; 53: 737–740
   PubMedGoogle Scholar
• Weissglas M., Schamhart D., Lowik C., Papapoulos S., Vos P., Kurth K. H. Hypercalcemia and cosecretion of interleukin 6 and parathyroid hormone related peptide by human renal cell carcinomas implanted into nude mice. J. Urology 1995; 153: 854–857
   PubMedGoogle Scholar
• Yoneda T., Alsina M. M., Chavez J. B., Bonewald L., Nishimura R., Mundy G. R. Evidence that splenic tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia and leukocytosis in a human tumor in nude mice. J. Clin. Invest. 1991; 87: 977–985
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Favrot M., Rossi J. F., Wijdenes J. Role of interleukin 6 in paraneoplastic thrombocytosis. Blood 1993; 87: 2261–2262
   Google Scholar
• Tartour E., Adams D., Besancenot J. F., Fridman W. H., Schlumberger M. Poems syndrome with high interleukin (IL)6 and IL1β serum levels, in a patient with thyroid carcinoma and melanoma. Eur. J. Cancer 1994; 30A: 894–895
   PubMedGoogle Scholar
• Keller U. Pathophysiology of cancer cachexia. Supportive Care in Cancer 1993; 6: 290–294
   Google Scholar
• Greenberg A. S., Nordan R. P., McIntosh J., Calvo J. C., Scow R. O., Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992; 52: 4113–4116
   PubMed Web of Science ®Google Scholar
• Mule J. J., Yang J. C., Lafreniere R. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin 2. J. Immunol. 1987; 139: 285–294
   PubMed Web of Science ®Google Scholar
• Thompson J. A., Peace D. J., Klarnet J. P., Kern D. E., Greenberg P. D., Cheever M. A. Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J. Immunol. 1986; 137: 3675–3680
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T., Seipp C. A., Simpson C., Richert C. M. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med. 1985; 313: 1485–1492
   PubMed Web of Science ®Google Scholar
• West W. H., Tauer K. W., Yannelli J. R., Aeshall G. D., Osr D. W., Thurman G. B., Oldham R. K. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan M., Robertson C. N., Lee R. E., Rubin J. T., Steipp C. A., Simpson C. G., White D. E. A progress report on the treatment of 157 patients with advanced cancer using lympholine-activated killer cells and interleukin-2 alone. N. Engl. J. Med. 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Parkinson D. R., Abrams J. F., Wiernik P. H., Rayner A. A., Margolin K. A., VanEcho D. A., Sznol M., Dutcher J. P., Aronson F. R., Doroshow J. H., Atkins M. B., Hawkins M. J. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol. 1990; 8: 1650–1656
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 1992; 10: 180–199
   PubMed Web of Science ®Google Scholar
• Dorval T., Mathiot C., Chosidow O., Revuz J., Avril M. F., Guillaume J. C., Tursz T., Brandely M., Pouillart P., Fridman W. H. Phase II trial in metastatic melanoma; analysis of clinical and immunological parameters. Biotechnol. Ther. 1992; 3: 63–79
   PubMedGoogle Scholar
• Legha S. S., Gianan M. A., Plager C., Eton O. E., Papadopoulous N. E. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77(1)89–96
   PubMed Web of Science ®Google Scholar
• Goedegebuure P. S., Douville L. M., Li H., Richmond G. C., Schoof D. D., Scavone M., Eberlein T. J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol. 1995; 13(8)1939–1949
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and mterleukin-2. J. Nat. Cancer Inst. 1994; 86(15)1159–1166
   PubMed Web of Science ®Google Scholar
• Tartour E., Mathiot C., Fridman W. H. Current status of interleukin 2 therapy in cancer. Biomed & Pharmacother. 1992; 46: 473–484
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Kärfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin 2 and interferon-a2b in advanced human malignancies. Lancet 1990; 335: 1509–1512
   PubMed Web of Science ®Google Scholar
• Thiounn N., Mathiot C., Dorval T., Tartour E., Mosseri V., Zerbib M., Fridman W. H., Debre B. Lack of efficacy of low dose subcutaneous recombinant interleukin 2 and interferon-a in the treatment of metastatic renal cell carcinoma. Br. J. Urology 1995; 75: 586–589
   PubMedGoogle Scholar
• Yang J. C., Topalian S. L., Schwartzentruber D. J., Parkinson D. R., Marincola F. M. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995; 76(4)687–694
   PubMed Web of Science ®Google Scholar
• Tartour E., Blay J. Y., Dorval T., Escudier B., Mosseri V., Douillard J. Y., Deneux L., Gorin I., Negrier S., Mathiot C., Pouillart P., Fridman W. H. Predictors of clinical response to interleukin 2-based immunotherapy in melanoma patients: a french multiinstitutional study. J. Clin. Oncol. 1996; 14: 1697–1703
   PubMed Web of Science ®Google Scholar
• Simpson W. G., Heys S. D., Whiting P. H. Acute phase proteins and recombinant IL2 therapy: prediction of response and survival in patients with colorectal cancer. Clin. Exp. Immunol. 1995; 99: 143–147
   PubMedGoogle Scholar
• Minasian L. M., Motzer R. J., Gluck L., Mazumdar M., Vlamis V., Krown S. E. Interferon alpha-2a in advanced renal cell carcinoma. Treatment results and survival in 159 patients with long term follow up. J. Clin. Oncol. 1993; 11: 1368–1375
   PubMed Web of Science ®Google Scholar
• Marincola F. M., Withe D. E., Wise A. P., Rosenberg S. A. Combination therapy with interferon alpha-éa and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 1995; 13: 1110–1122
   PubMed Web of Science ®Google Scholar
• Negrier S., Escudier B., Lasset C., et al. The FNCLCC Crecy trial: interleukin-2 (IL2)+Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 1996; 15: 629
   Google Scholar
• Pujade-Lauraine E., Guastalla J. P., Colombo N., Devilier P., Francois E., Fumoleau P., Monnier A., Nooy M., Mignot L., Bugat R., Marques C., Mousseau M., Netter G., Maloisel F., Larbaoui S., Brandely M. Intraperitoneal recombinant interferon gamma in ovarian cancer with residual disease at second look laparatomy. J. Clin. Oncol. 1996; 14: 343–350
   PubMed Web of Science ®Google Scholar
• Meyskens F. L., Kopecky K. J., Taylor C. W., Noyes R. D., Tuthill R. J., Hersh E. M., Feun L. G., Doroshow J. H., Flaherty L. E., Sondak V. K. Randomized trial of adjuvant human interferon gamma versus observation in high risk cutaneous melanoma: a southwest oncology group study. J. Nat. Cancer Inst. 1995; 87: 1710–1712
   PubMedGoogle Scholar
• Kirkwood J. M. Biological therapy of melanoma. Proc. Amer. Assoc. Cancer Res. 1996; 37: 643
   Google Scholar
• Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J. Recombinant IL-12 administration induces tumor regression in association with IFN gamma production. J. Immunol. 1994; 153: 1697–1706
   PubMed Web of Science ®Google Scholar
• Brunda M. J., Luistro L., Warner R. R., Wright R. B., Hubbard B. R., Murphy M. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 1993; 178: 1223–1230
   PubMed Web of Science ®Google Scholar
• Desai B. B., Quinn P. M., Wolitzky A. G., Mongini P. K., Chizzonite R., Gately M. K. IL12 receptor. II Distribution and regulation of receptor expression. J. Immunol. 1992; 148: 3125–3132
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008–4027
   PubMed Web of Science ®Google Scholar
• Wigginton J. M., Komschlies K. L., Back T. C., Franco J. L., Brunda M. J., Wiltrout R. H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Nat. Cancer Inst. 1996; 88: 38–43
   PubMed Web of Science ®Google Scholar
• VanOstade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., Lesslauer W., Tavernier J., Brouckaert P., Fiers W. Human TNF mutants with selective activity on the p55 receptor. Nature 1993; 361: 266–269
   PubMedGoogle Scholar
• Mule J. J., McIntosh J. K., Jablons D. M., Rosenberg S. A. Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med. 1990; 171: 629–636
   PubMed Web of Science ®Google Scholar
• Ravoet C., DeGreve J., Vandewoude K., Kerger J., Soulier J. P., Lacor P., Stryckmans P., Piccart M. Tumour stimulating effects of recombinant human interleukin 6. Lancet 1994; 344: 1576–1577
   PubMed Web of Science ®Google Scholar
• Flaherty L. E., Liu P. Y., Fletcher W. S., et al. Dacarbazine and out patient interleukin-2 in treatment of metastatic malignant melanoma: a phase II southwest oncology group trial. J. Natl. Cancer Inst. 1992; 84: 893–894
   PubMedGoogle Scholar
• Fiedler W., Jasmin C., DeMulder P. H.M., et al. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur. J. Cancer 1992; 28: 443–446
   PubMedGoogle Scholar
• Demchak P. A., Mier J. W., Robert N. J., et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J. Clin. Oncol. 1991; 9: 1821–1830
   PubMed Web of Science ®Google Scholar
• Mitchell M. S. Chemotherapy in combination with biomodulation: a 5 year experience with cyclophosphamide and interleukin-2. Semin. Oncol. 1992; 19(2 suppl. 4)80–87
   PubMedGoogle Scholar
• Flaherty L. E., Redman B., Marino S., et al. High dose dacarbazine and cisplatin alone and combined with outpatient interleukin-2 in metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 1992; 11: 350, poster no. 1206, 1992.
   Google Scholar
• Veelken H., Rosenthal F. M., Schneller F., et al. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotechnol. Ther. 1992; 3: 1–4
   PubMedGoogle Scholar
• Kruit W. H.J., Goey S. H., Monson J. R.T., et al. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma. Br. J. Haematol. 1992; 79: 84s–86s
   Google Scholar
• Budd G. T., Murphy S., Finke J., et al. Phase I trial of high-dose bolus interieukin-2 and interferon alfa-2a in patients with metastatic malignancy. J. Clin. Oncol. 1992; 10: 804–809
   PubMedGoogle Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 1989; 7: 1893–1874
   Google Scholar
• Khayat D., Borel C., Tourani J. M., Benhammouda A., Antoine E., Rixe O., Vuillemin E., Bazex P. A., Thill L., Franks R., Auclerc G., Soubrane C., Banzet P., Weil M. Sequential chemoimmunotherapy with cisplatin interleukin 2 and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol. 1993; 11: 2173–2180
   PubMed Web of Science ®Google Scholar
• Richards J. M., Metha N., Ramming K., Skosey P. Sequential chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol. 1992; 10: 1338–1343
   PubMed Web of Science ®Google Scholar
• Legha S. A., Plager C., Ring S., et al. A phase II study of biochemotherapy using interleukin-2 + interferon alpha-2a in combination with cisplatin, vinblastine and DTIC in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol., poster no. 1179, 1992. J. Clin. Oncol. 1992; 11: 343
   Google Scholar
• Atkins M. B., O'Boyle K. R., Sosman J. A., Weiss G. R., Margolin K. A., Ernest M. L., Kappler K., Mier J. W., Sparano J. A., Fisher R. I. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol. 1994; 12: 1553–1560
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Lopez-Hanninen E., Kirchner H., Franzke A., Korfer A. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur. J. Cancer 1995; 31A: 876–881
   PubMed Web of Science ®Google Scholar
• Merluzzi V. J., Welte K., Savage D. M. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro, in vivo by purified human interleukin 2. J. Immunol 1983; 131: 806–809
   PubMed Web of Science ®Google Scholar
• Dorval T., Negrier S., Chevreau C., Baume D., Cupissol D., Oskam R., DePeuter M. A., Herrera A., Escudier B. Results of a French multicentric randomized trial of chemoimmunotherapy. Proc. Am. As. Soc. Clin. Oncol. 1994; 13: 395
   Google Scholar
• Lippman S. M., Parkinson D. R., Itri L. M., Weber R. S., Stimson P., Schantz S. P., Ota D. M., Schusterman M. A., Krakoff I. H., Gutterman J., KiHong W. 13-cis-retinoic acid and interferon alpha-2a. Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Nat. Cancer Instit. 1992; 84: 235–241
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Schwartz L., Murray L. T., Murphy B. A., Hoffman A. D., Albino A. P., Vlamis V., Nanus M. D. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol. 1995; 13: 1950–1957
   PubMed Web of Science ®Google Scholar
• Lopez-Hanninen E., Kirchner H., Atzpodien J. Interleukine-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 1996; 155: 19–25
   PubMedGoogle Scholar
• Suzuki H., Yasukawa K., Saito T., Goitsuka R., Hasegawa A., Ohsugi Y., Taga T., Kishimoto T. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol. 1992; 22: 1989–1993
   PubMed Web of Science ®Google Scholar
• Bataille R., Barlogie B., Lu Z. Y., Rossi J. F., Lavabre-Bertrand T., Beck T., Wijdenes J., Brochier J., Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–691
   PubMed Web of Science ®Google Scholar
• Beck J. T., Hsu S. M., Wijdenes J., Bataille R., Klein B., Vesole D., Hayden K., Jagannath S., Barlogie B. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 1994; 330: 602–605
   PubMed Web of Science ®Google Scholar
• Trojan J., Johnson T. R., Rudin S. D., Ulan J., Tykocinski M. L., Lian J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor IRNA. Science 1993; 259: 94–97
   PubMedGoogle Scholar
• Seung L. P., Rowley D. A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Nat. Acad. Sci. USA 1995; 92: 6254–6258
   PubMed Web of Science ®Google Scholar
• Schmidt W., Schweighoffer T., Herbst E., Maass G., Berger M., Schilder F., Schaffner G., Birnstiel M. L. Cancer vaccines: the interleukin 2 dosage effect. Proc. Nat. Acad. Sci. USA 1995; 92: 4711–4714
   PubMed Web of Science ®Google Scholar
• Fearon E. R., Pardoll D. M., Itaya T., Golumbeck P., Levitsky H. I., Simons J. W., Darasuyama H., Vogelstein B., Frost P. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf G. D., Schmidt-WolfIngo G. H. Cytokines and gene therapy. Immunol. Today 1995; 16: 173–175
   PubMedGoogle Scholar
• Golumbek P., Lazenby A., Levitsky H., Jaffee E., Karasuyama H., Kaker M., Pardoll D. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Rubin J. T., Carty S., Edington H., Ferson P., Landreneau R., Pippin B., Posner M., Rosenfelder D., Watson C. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Ther. 1994; 5: 41–55
   PubMed Web of Science ®Google Scholar
• Unterhuber R. Gene therapy gaters speed in Germany. Nature 1993; 365: 197
   PubMedGoogle Scholar
• Golumbek P., Azhari R., Jaffee E. M., Levitsky H. I., Lazenby A., Leong K., Pardoll D. Controlled release biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993; 53: 5841–5844
   PubMed Web of Science ®Google Scholar
• Roth C., Mir L. M., Cressent M., Quintin-Colonna F., Belehradek J., Ley V., Fradelizi D., Kourilsky P. Inhibition de la croissance tumorale induite par l'injection de cellules histo-incompatibles produisant de l'interleukine 2. Cr. Acad. Sci. Paris 1992; 314: 499–504, Série III
   PubMedGoogle Scholar
• Becker J. C., Pancook J. D., Gillies S. D., Mendelsohn J., Reisfeld R. A. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Nat. Acad. Sci. USA 1996; 93: 2702–2707
   PubMedGoogle Scholar
• Boon T., Cerottini J. C., Van den Eynde B., Van der Bruggen P., VanPal A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994; 12: 337–365
   PubMed Web of Science ®Google Scholar
• Noguchi Y., Richards E., Chen Y. T., Old L. J. Influence of interleukin 12 on p53 peptide vaccination against established meth A sarcoma. Proc. Nat. Acad. Sci. 1995; 92: 2219–2223
   PubMed Web of Science ®Google Scholar
• Chen T., Tao M. H., Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL2, IL4 and granulocyte-macrophage colony stimulating factor. J. Immunol. 1995; 153: 4775–4787
   Google Scholar